BrainStorm Cell Therapeutics: Another Clinical-Stage Small Firm’s Product for the Devastating Disease ALS

BrainStorm Cell Therapeutics Inc
BrainStorm Cell Therapeutics Inc (BCLI) develops innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of the NurOwn® technology platform used to produce autologous MSC-NTF cells through an exclusive, worldwide licensing agreement.

Autologous MSC-NTF cells have received Orphan Drug designation status from the U.S. FDA . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.